LONDON, June 17, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Bioabsorbable Stents in Thousand Units and in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 15 companies including many key and niche players such as -
Abbott Laboratories
Amaranth Medical, Inc.
Arterial Remodeling Technologies SA
BIOTRONIK SE & Co. KG
Elixir Medical Corp.
Download the full report: https://www.reportbuyer.com/product/1171460/
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Bioabsorbable Stents - Transforming the Interventional
Cardiology Market II-1
Evolution of Coronory Stents II-2
Global Coronory Stents Market - A Few Key Facts II-3
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in
Future II-3
How are Bioabsorbable Stents Better than Drug-Eluting and
Bare Metal Stents II-4
Clinical Trial Results Corroborate BVS Therapy II-4
Market Overview II-5
Table 1: Bioabsorbable Stents Market Potential: Percentage
Share Breakdown of Revenues for Bare Metal Stents, Drug
Eluting Stents, and Bioabsorbable Stents (includes
corresponding Graph/Chart) II-6
Current & Future Analysis II-6
Growth Drivers II-7
Absorb® - The First Commercially Available Bioabsorbable Stent II-7
Competition - Abbott Leads the Race II-7
Bioabsorbable Stents in Pipeline: 2013 II-8
Europe - The Largest Market for Biabsorbable Stents II-9
Developing Countries - Hot Spots for Growth II-9
Market Challenges and Threats II-10
Technological Challenges II-10
Safety- Efficacy Factor II-10
Regulatory Challenges II-10
Price Factor II-10
Alternative Therapies/Devices: Threats to Coronary Stents II-11
Cell Transplantation - A Threat to Coronary Stents II-11
2. MARKET TRENDS, DRIVERS & CHALLENGES II-12
Global Menace of Coronary Artery Disease - A Major Growth Driver II-12
Table 2: Global Annual Medical Cost of CVD in US$ Billion
(2010-2030) (includes corresponding Graph/Chart) II-12
Table 3: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others (includes corresponding
Graph/Chart) II-12
Table 4: Fatalities in Low Income Countries by Health
Disorder (2015 & 2030): Projected Percentage Breakdown of
Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria;
Malnutrition; and Others (includes corresponding Graph/Chart) II-13
Table 5: Fatalities in Mid Income Countries by Health
Disorder (2015 & 2030): Projected Percentage Breakdown of
Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria;
Malnutrition; and Others (includes corresponding Graph/Chart) II-14
Table 6: Fatalities in High Income Countries by Health
Disorder (2015 & 2030): Projected Percentage Breakdown of
Number of Deaths for CVD, Cancer, Injury, and Others
(includes corresponding Graph/Chart) II-14
Restenosis Creates the Need for Bioabsorbable Stents II-15
Ageing Demographics and Longer Life Expectancy Bolsters Market
Growth II-15
Table 7: Global Population Statistics for the 65+ Age Group
(2013) (includes corresponding Graph/Chart) II-16
Table 8: Life Expectancy by Select Countries: 2013 (includes
corresponding Graph/Chart) II-17
Rising Middle Class Population Aids Growth II-17
Table 9: World Middle Class Population (2012 & 2030F):
Percentage Share Breakdown by Region - North America, Europe,
Asia-Pacific, Latin America, and The Middle East & Africa
(includes corresponding Graph/Chart) II-18
Rising Healthcare Expenditure: Opportunities in Store II-18
Table 10: Per-Capita Healthcare Expenditure in Select Regions
(2013) (includes corresponding Graph/Chart) II-19
Table 11: Top 20 Countries with the Highest Healthcare
Spending as a Percentage of GDP (2012) (includes
corresponding Graph/Chart) II-19
Risk of CAD in Obesity Offers Prospects for Coronary Stenting II-20
Table 12: Global Obese Population in Millions by
Region/Country (2013) (includes corresponding Graph/Chart) II-21
Table 13: Global Obesity Levels (2013): Percentage Share
Breakdown of Total Obese Population by Leading Countries
(includes corresponding Graph/Chart) II-21
Diabetics at Higher Risk of Heart Diseases II-21
Table 14: Worldwide Prevalence of Diabetes Mellitus by
Geographic Region (2013 & 2035P) (includes corresponding
Graph/Chart) II-22
The Hypertension-Cholesterol Link to Drive Demand II-23
Table 15: Death Rates Due to Hypertension in Select
Countries: 2011 II-23
Table 16: Percentage Prevalence Rate of High Blood Pressure
for Patients over 25 Years of Age by Region (1980 & 2010)
(includes corresponding Graph/Chart) II-25
Spurt in Medical Tourism Offers Growth Opportunities II-25
3. PIPELINE ANALYSIS II-26
ART Bioabsorbable Stent (Arterial Remodeling Technologies,
France) II-26
DREAMS (BIOTRONIK, Germany) II-26
DESolve™ Coronary Scaffold (Elixir Medical, US) II-26
IGAKI-TAMAI® (Kyoto Medical Planning, Japan) II-26
ReZolve® (REVA Medical Inc., US) II-27
IDEAL (Bioabsorbable Therapeutics, US) II-27
Magnesium-Based Stent (Luxfer, UK) II-27
LifeTech Iron (LifeTech, China) II-28
The Xinsorb BRS (Huaan Biotechnology Group, China) II-28
4. REGULATORY FRAMEWORK II-29
The United States II-29
Europe II-29
Australia II-29
5. PRODUCT OVERVIEW II-30
Coronary Artery Disease (CAD) - A Perspective II-30
Causes and Symptoms II-30
Treatment Options for Coronary Artery Disease II-30
Percutaneous Coronary Intervention (PCI) II-31
Coronary Stenting II-31
Types of Coronary Stents II-31
Bare Metal Stents (BMS) II-31
Drug Eluting Stents (DES) II-32
Bioabsorbable Stents II-32
Design and Composition of Bioabsorbable Stents II-33
Different Types of Bioabsorbable Stents II-33
Metallic Bioabsorbable Stents II-33
Polymer Bioabsorbable Stents II-33
Degradation Period of Select Bioabsorbable Materials II-34
Challenges II-34
Other Treatment Options for Coronary Heart Disease II-35
Coronary Artery Bypass Grafting (CABG) II-35
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) II-35
TransMyocardial Laser Revascularization (TMR) II-35
Peripheral Arterial Disease: Understanding the Stealthy Peril II-35
Treatment for PAD II-36
Lifestyle Changes II-36
Medication II-36
Surgery II-37
Stenting- A Treatment Option for PAD II-37
6. RECENT INDUSTRY ACTIVITY II-38
Elixir Receives CE Approval for Bioresorbable Stent II-38
Arterial Remodeling Signs Collaboration Agreement with Terumo II-38
Abbott Concludes Enrollment for Absorb Clinical Trials for US,
China, and Japan II-38
Abbott Initiates Clinical Trials of ABSORB IV BVS II-38
Abbott Initiates Japanese Clinical Trial of Absorb™ BVS II-38
Abbott Initiates ABSORB III Clinical Trial in the US II-38
ART Conducts First-in-Human Clinical Trial of ART
Bioabsorbable Stent II-39
Kyoto Medical Releases Long-Term Safety and Efficacy Data for
its IGAKI-TAMAI® Stent II-39
Abbott Laboratories Launches Absorb BVS in Europe and Other
Markets II-39
7. FOCUS ON SELECT GLOBAL PLAYERS II-40
Abbott Laboratories (US) II-40
Amaranth Medical, Inc. (US) II-40
Arterial Remodeling Technologies SA (France) II-40
BIOTRONIK SE & Co. KG (Germany) II-41
Elixir Medical Corp. (US) II-41
Kyoto Medical Planning Co., Ltd. (Japan) II-42
REVA Medical, Inc. (US) II-42
8. GLOBAL MARKET PERSPECTIVE II-43
Unit Sales II-43
Table 17: World Current and Future Analysis for Bioabsorbable
Stents by Geographic Region - US, Europe, Asia-Pacific and
Rest of World Markets Independently Analyzed with Annual
Sales in '000 Units for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-43
Table 18: World 7-Year Perspective for Bioabsorbable Stents
by Geographic Region - Percentage Breakdown of Unit Sales for
US, Europe, Asia-Pacific and Rest of World Markets for Years
2014 and 2020 (includes corresponding Graph/Chart) II-44
Value Sales II-45
Table 19: World Current and Future Analysis for Bioabsorbable
Stents by Geographic Region - US, Europe, Asia-Pacific and
Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-45
Table 20: World 7-Year Perspective for Bioabsorbable Stents
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Europe, Asia-Pacific and Rest of World Markets for
Years 2014 and 2020 (includes corresponding Graph/Chart) II-46
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Growth Indicators III-1
Rising CVD Incidence - A Major Growth Driver III-2
Table 21: Cardiovascular Disease Incidence in the US by
Gender & Age Group (per 1,000 Adults) (includes
corresponding Graph/Chart) III-2
Table 22: Leading Causes of CVD Fatalities in the US:
Percentage Breakdown of Mortality for Coronary Heart
Disease, HBP, Heart Failure, Stroke, and Others (includes
corresponding Graph/Chart) III-2
Ageing Population - A Vital Demography III-3
Table 23: North American Elderly Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-3
Challenges Ahead III-3
Strategic Corporate Developments III-4
Select Key Players III-5
B.Market Analytics III-7
Table 24: The US Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-7
Table 25: The US Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-8
2. EUROPE III-9
A.Market Analysis III-9
The Largest Market for Bioabsorbable Stent III-9
Growth Drivers III-9
Cardiovascular Disease in Europe - A Perspective III-10
Europe - A Highly Diverse Market III-10
Absorbable Stents & the Controversies Surrounding Them III-10
Ageing Population Boosts Demand for Biodegradable Stents III-11
Table 26: European Country-wise Statistics of 60+
Population as % of Total Population: 2013 (includes
corresponding Graph/Chart) III-12
Product Launch III-13
B.Market Analytics III-13
Table 27: European Current and Future Analysis for
Bioabsorbable Stents by Geographic Region - France, Germany,
Italy, UK, and Rest of Europe Markets Independently Analyzed
with Annual Sales in '000 Units for Years 2013 through 2020
(includes corresponding Graph/Chart) III-13
Table 28: European 7-Year Perspective for Bioabsorbable
Stents by Geographic Region - Percentage Breakdown of Unit
Sales for France, Germany, Italy, UK, and Rest of Europe
Markets for Years 2014 and 2020 (includes corresponding
Graph/Chart) III-14
Table 29: European Current and Future Analysis for
Bioabsorbable Stents by Geographic Region - France, Germany,
Italy, UK, and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) III-15
Table 30: European 7-Year Perspective for Bioabsorbable
Stents by Geographic Region - Percentage Breakdown of Dollar
Sales for France, Germany, Italy, UK, and Rest of Europe
Markets for Years 2014 and 2020 (includes corresponding
Graph/Chart) III-16
2a. FRANCE III-17
A.Market Analysis III-17
Strategic Corporate Developments III-17
Select Player III-17
B.Market Analytics III-18
Table 31: French Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-18
Table 32: French Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-19
2b. GERMANY III-20
A.Market Analysis III-20
Select Player III-20
B.Market Analytics III-21
Table 33: German Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-21
Table 34: German Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-22
2c. ITALY III-23
Market Analysis III-23
Table 35: Italian Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-23
Table 36: Italian Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-24
2d. THE UNITED KINGDOM III-25
Market Analysis III-25
Table 37: The UK Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-25
Table 38: The UK Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-26
2e. REST OF EUROPE III-27
Market Analysis III-27
Table 39: Rest of European Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-27
Table 40: Rest of European Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-28
3. ASIA-PACIFIC III-29
A.Market Analysis III-29
The Fastest Growing Market for Bioabsorbable Stents III-29
Growth Drivers III-29
Aging Populace - Potential Opportunities III-30
Table 41: Over 65 Years Individuals as % of the Total
Population in Select Asian Countries (includes
corresponding Graph/Chart) III-30
Asia-Pacific - A Price Sensitive Market III-30
India & China Offer Significant Growth Opportunities III-30
Table 42: China and India Lead Global Population (July
2013): Table Depicting China and India's Huge Population
Vis-a-vis Other Countries' Population (in Million) by Age
Group (includes corresponding Graph/Chart) III-31
Focus on Select Markets III-31
India III-31
A High Potential Market III-31
Unethical Medical Practices Mar Business Prospects III-32
Japan III-32
Prospects Weighed down by Regulatory Entanglements III-32
Bioabsorbable Stents Status in Japan III-32
Japanese Coronary Stents Command Higher Prices III-33
China III-33
Healthcare Reforms to Propel Stent Market III-33
Strategic Corporate Development III-33
Kyoto Medical Planning Co., Ltd. - A Key Player III-34
B.Market Analytics III-34
Table 43: Asia-Pacific Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-34
Table 44: Asia-Pacific Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-35
4. REST OF WORLD III-36
Market Analysis III-36
Table 45: Rest of World Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-36
Table 46: Rest of World Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in US$ Million for
Years 2013 through 2020 (includes corresponding Graph/Chart) III-37
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 15 (including Divisions/Subsidiaries - 16)
The United States (9)
Japan (1)
Europe (3)
- France (1)
- Germany (1)
- The United Kingdom (1)
- Asia-Pacific (Excluding Japan) (3)
Download the full report: https://www.reportbuyer.com/product/1171460/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article